SCHEMBL19414364

SCHEMBL19414364

Nc1ncnc2[nH]nc(-c3ccccc3CO)c12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 4/20 0.43
EGFR P00533 3/20 0.43
ABL1 P00519 3/20 0.43
ABL2 P42684 2/20 0.43
PIK3CD O00329 6/20 0.43
PIK3CA P42336 5/20 0.43
PIK3CB P42338 5/20 0.43
PIK3CG P48736 5/20 0.43
PRKDC P78527 5/20 0.43
ATR Q13535 2/20 0.39
ADORA2A P29274 2/20 0.38
HTR2B P41595 1/20 0.38
GPR68 Q15743 1/20 0.38
CDK9 P50750 2/20 0.37
CCNT1 O60563 1/20 0.37
CCNE2 O96020 1/20 0.37
CCNE1 P24864 1/20 0.37
CDK2 P24941 1/20 0.37
KDR P35968 4/20 0.36
TEK Q02763 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30386850 0.81 PIK3CD (0.59) SRCEGFRABL1PIK3CDPIK3CA
SCHEMBL27774340 0.81 PIK3CD (0.59) SRCEGFRABL1PIK3CDPIK3CA
SCHEMBL21048476 0.78 PIK3CG (0.59) SRCEGFRPIK3CDPIK3CAPIK3CB
SCHEMBL23917208 0.74 MAP2K4 (0.48) SRCEGFRABL1ABL2PIK3CD
SCHEMBL408618 0.74 PIK3CD (0.55) SRCEGFRABL1ABL2PIK3CD
SCHEMBL16654444 0.74 ADORA2A (0.36) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL30387798 0.73 PIK3CD (0.61) SRCEGFRABL1PIK3CDPIK3CA
SCHEMBL19385334 0.73 LCK (0.47) SRCPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL16665784 0.73 PIK3CD (0.55) SRCEGFRABL1ABL2PIK3CD
SCHEMBL130417 0.72 PIK3CD (0.55) SRCEGFRABL1ABL2PIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11020399-B2 Intermediates useful in the synthesis of compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2021-06-01 US disclosed
US-20200239427-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2020-07-30 US disclosed
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2019-10-15 US disclosed
US-20190282581-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS AG (CH) 2019-09-19 US disclosed
US-10322130-B2 Substituted chromenones as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2019-06-18 US disclosed
US-20190105324-A9 SUBSTITUTED CHROMENONES AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS AG (CH) 2019-04-11 US disclosed
US-10220035-B2 Compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2019-03-05 US disclosed
US-20180110783-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS SA (CH) 2018-04-26 US disclosed
US-9775841-B2 Compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2017-10-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases PIK3CB, PIK3CD, PDPK1 SRC 202/4885EGFR 929/4885ABL1 329/4885
US-11020399-B2 Intermediates useful in the synthesis of compounds as modulators of protein kinases MAP4K2, MAP3K20, MAP3K1 SRC 85/4885EGFR 520/4885ABL1 106/4885
US-20190105324-A9 SUBSTITUTED CHROMENONES AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKAR2B SRC 254/4885EGFR 1502/4885ABL1 464/4885
US-10220035-B2 Compounds as modulators of protein kinases PRKCA, PRKCH, PRKCE SRC 205/4885EGFR 1203/4885ABL1 297/4885
US-20180110783-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB SRC 285/4885EGFR 1359/4885ABL1 334/4885
US-20190282581-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB SRC 285/4885EGFR 1359/4885ABL1 334/4885
US-20200239427-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB SRC 314/4885EGFR 1667/4885ABL1 465/4885
US-10322130-B2 Substituted chromenones as modulators of protein kinases MAP3K1, CSNK1A1, MAP3K2 SRC 90/4885EGFR 807/4885ABL1 376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.